Study wrapper · #1378
Semaglutide and Tirzepatide for the treatment of MASH: What Works, What's Coming, and What's Missing.
Chirapongsathorn S, Tacke F Digestion. 2026.
DOI: 10.1159/dig/acmag014PubMed: 42715139
Editor's note
A narrative review, so it synthesizes rather than adds evidence, but its anchors are solid: interim phase 3 data behind semaglutide's accelerated MASH approval and consistent phase 2 fibrosis signals for tirzepatide. The open questions it flags — durability, long-term liver outcomes, safety over years — are the right ones. Senior author Tacke is a leading name in hepatology, which lends weight to the framing.
Plain-language abstract
A review of incretin drugs for fatty liver disease (MASLD/MASH), summarizing phase 2 and 3 data showing semaglutide and tirzepatide can resolve steatohepatitis and in some cases improve liver fibrosis, and noting semaglutide's accelerated approval for non-cirrhotic MASH with moderate fibrosis.
Related coverage
Weak / none
Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial.
Journal of medical economicsn=——2026
Mixed
Sleeve gastrectomy versus tirzepatide to improve survival among patients with stage 5 CKD: A Markov decision analysis.
American journal of surgeryn=——2026
Mixed
Development and validation of a multiplexed LC-HRMS method for nine GLP-1 receptor agonists and its pharmaceutical application.
Journal of chromatography. An=——2026